

HIV Research @ the SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH AIDS Office


Erin Wilson Research Scientist, SFDPH <u>erin.wilson@sfdph.org</u>

Associate Professor, Dept of Epidemiology and Biostatistics, UCSF





SFDPH AIDS OFFICE





CENTER FOR LEARNING AND INNOVATION

SUMMER HIV/AIDS RESEARCH PROGRAM



https://sharpinternship.org/







https://getsfcba.org/

ARCHES -HIV EPIDEMIOLOGY AND CORE SURVEILLANCE SECTION



Wayne Enanoria, PhD, MPH Ling Hsu, MPH

- PROVIDE METRICS TO MONITOR SUCCESS OF ALL GETTING TO ZERO STRATEGIC INITIATIVES
 - CORE HIV/AIDS SURVEILLANCE
 - MOLECULAR HIV SURVEILLANCE
 - MEDICAL MONITORING PROJECT

HIV Epidemiology

Annual Report

San Francisco Department of Public Health Population Health Division

HIV EPIDEMIOLOGY AND SURVEILLANCE

- MONITOR INCIDENCE, PREVALENCE, MORBIDITY AND MORTALITY OF PERSONS WITH HIV/AIDS IN SAN FRANCISCO, FOLLOWING GOVERNMENT MANDATES
 - AIDS CASE REPORTING SINCE 1981, NAME-BASED HIV CASE REPORTING SINCE 2006
 - MANDATORY DUAL REPORTING BY PROVIDER AND LABORATORY OF HIV TEST RESULTS INCLUDING ALL VIRAL LOAD AND CD4 TEST RESULTS
- LONGITUDINAL REGISTRY
 - FOLLOW-UP CHART REVIEWS FOR ART, PROPHYLAXIS, OIS, SUBSTANCE USE INCLUDING DRUG AND TOBACCO USE
 - CURRENT ADDRESS AND HOUSING STATUS
 - DEATHS AND MULTIPLE CAUSES OF DEATH


https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/AnnualReport2019 _Indigo_20200929_Web_fixed.pdf the center for public health research.

CENTER FOR PUBLIC HEALTH RESEARCH



National HIV Behavioral Surveillance (NHBS) CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) PI, MCFARLAND





- Novel Social Epidemiological cross sectional & longitudinal research
 - Domestic & International
- Data > Interventions
- Mentorship and training
- Collaborative research projects with other units @ the SFDPH



TRUE -TRANS RESEARCH UNIT FOR EQUITY

TRUESF.ORG

Relationships Aren' t black Or white

if you are a transamorous cis man in the SF Bay Area,

we want to hear from you.

The Partners Study is a project of the Trans Research Unit for Equity at the San Francisco Department of Public Health. Participants can earn \$75-115. Call us @ 415-652-5915 for more information or to schedule an interview.



SHINE STRONG



BRILHAR E TRANSCENDER INTERVENTION NIH UG3/UH3 PI, WILSON/GRINSZTEJN



SWEEKAR

NIH FOGARTY R21 > R34 PI, WILSON



THE STAY STUDY

CALIFORNIA HIV/AIDS RESEARCH (CHRP) PROGRAM, PIS LIU/WILSON



CENTER ON SUBSTANCE USE AND HEALTH OBSERVATIONAL STUDIES

You can improve

the future of pain

Ongoing Trials and Observational Studies

Chart review



Glenn-Milo Santos, PhD TRANSITIONS You can improve

management. the future of pain COPING management. COPING **Transitions** ODS People prescribed People prescribed People prescribed opioids **Population &** opioids (N= 600) opioids (N= 300-400) (N = 600)Observational Observational Observational Intervention Pain and function **HIV** outcomes Illicit opioid use

Longitudinal cohort, up to 4yr f/u

Longitudinal, retrospective cohort

Phillip Coffin, MD

Setting

Primary outcome

Design



Recently Completed/Ongoing Pharmacologic Intervention Trials

Glenn-Milo Santos, PhD







	Curb the Line (Analysis Phase)	Say When	Harness
Population	People with cocaine Use disorders (N=45)	MSM who binge-drink alcohol (N=120)	People with alcohol use disorders (n=120)
Intervention & Control	ER Lorcaserin vs. placebo	Oral naltrexone vs. placebo, as-needed	Kudzu vs. placebo, as-needed
Outcome	Cocaine Use and Cocaine- Associated Sexual Risk Behaviors	Alcohol Use, Sexual Risk Behaviors	Alcohol Use, Sexual Risk Behaviors, STIs
Design	Double-blind RCT, 3 month f/u	Double-blind RCT, 3 month f/u	Double-blind RCT, 3 month f/u

BRIDGE HIV: A TRADITION OF INNOVATIVE RESEARCH TO PREVENT HIV/AIDS





Susan Buchbinder , MD

Albert Liu, MD, MPH



Hyman Scott, MD, MPH

Vaccines & Prep

- Recruitment and retention of at-risk cohorts Bisk factors for

- Risk factors for infection

- Per-contact risk

- Natural history

- Long term nonprogression (LTNP)

Cohort Study

- HIV antibody test

Behavioral & Biomedical Interventions

- Individualized, client centered counseling

- Preventive Vaccines

- STD interventions (HSV-2 suppression)

- Pre-exposure Prophylaxis generation of HIV

- Rectal and vaginal microbicides

- Peer navigation among Black and Latino MSM and trans people

- Home HIV and STI testing

Evaluating Platforms for Intervention Delivery and Building Research Capacity

- Combination Prevention*

- Implementation Research

- Fostering a new generation of HIV researchers

- mHealth



https://bridgehiv.org

microbicide trials network





HIV VACCINE TRIALS NETWORK

Continued on the next page...



Profile of Mosaico (HVTN 706/HPX3002)

- Study teams aim to enroll 3,800 cisgender men and transgender people who have sex with cisgender men and/or transgender people between the ages of 18-60 years.
- The study will take place at over 50 trial sites in the U.S., Mexico, Brazil, Peru, Argentina, Poland, Italy and Spain.
- Mosaico will evaluate an investigational mosaic-based vaccine regimen with the goal of determining if it is effective in preventing HIV infection in MSM and transgender individuals.
- Initial results from the study may be available by 2024.
- Public-private partnership making the search for a safe and globally effective preventive HIV vaccine possible
- Mosaico is supported by a public-private partnership led by Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson; the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH); and the NIAID-funded HIV Vaccine Trials Network (HVTN). Additional partners providing support include the U.S. Army Medical Research and Development Command (USAMRDC).

COVID-19 RESPONSE



 ONE OF 58 SITES PART OF A COVID-19 ANTIBODY STUDY - CHARACTERIZING SARS-COV-2-SPECIFIC IMMUNITY IN INDIVIDUALS WHO HAVE RECOVERED FROM COVID-19



TRIAL - ASTRAZENECA STUDY

https://www.sfchronicle.com/bay area/article/Bay-Area-joins-twomajor-coronavirus-vaccine-15479950.php

DID YOU TEST COVID-19 POSITIVE? Join a research study.

Bridge HIV has been a global leader in HIV prevention research for over three decades, serving the Bay Area community by targeting the global HIV pandemic. As your community partner, we are turning some of that focus to the global COVID-19 pandemic.

To stop the spread of this virus we need a vaccine and to discover one we need your help.

Did you test positive for COVID-19? We want to learn what immune responses help people with COVID-19 recover from their infection. You can help right now by joining a research study.

Text/Call: (415) 916-8732

COVIDresearch@sfdph.org

HELPFICHTHIV







San Francisco Department of Public Health



'Mom, I have HIV but don't worry about me': How One City Is Trying to Eliminate HIV

February 28, 2020 | Shanoor Seervai



https://www.commonwealthfund.org/publications/podcast/2 020/feb/mom-i-have-hiv-dont-worry-about-me-how-one-citytrying-eliminate-hiv